X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Researchers At Stanford Create A Novel Cancer Treatment

Content Team by Content Team
11th October 2022
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The molecule tigilanol tiglate, also known as EBC-46, could provide tailored treatment for diseases including cancer, as according research from Stanford University in the US that was recently published in the scientific journal Nature Chemistry.

The chemical is only naturally occurring in a tiny area of the northeastern Australian rainforest, in the fruit seeds of the blushwood tree (Fontainea picrosperma). Despite the compound’s complexity and difficulty in laboratory replication, Stanford researchers were able to create tigilanol tiglate.

Protein kinase C (PKC), which controls expression of genes and cell growth, is present in EBC-46. Small injections of EBC-46 into solid tumours changed the cellular signalling and activated specific PKC isoforms. This process affects the protein activity of malignant cells, resulting in the inflammation of tumours and the bleeding and degeneration of blood vessels.

The biotech company QBiotics in Australia first recognised tigilanol tiglate as having promise for application in medication development. The Stanford University team put this information to use and combined it for practical purposes.

The researchers utilised lab tools at the Stanford Cancer Institute Proteomics/Mass Spectrometry Shared Resource, the Stanford Sherlock cluster for computer modelling, and the Stanford Neuroscience Microscopy Service.

Researchers employed a Chinese herbal remedy called Croton tiglium (purging croton), which contains the active pharmaceutical ingredient (API) phorbol, to create the medication. The B ring of phorbol, which was chosen for alteration, received extra oxygen atoms.

His colleagues were able to accomplish what many people had assumed was impossible, said professor of chemistry at Stanford, Paul Wender, who also, graciously, teaches courses in chemical and systems biology.

They are learning more about how we can govern that functionality as we understand more about how cells function, he continued. This is crucial for dealing with rogue cells that cause diseases like cancer and Alzheimer’s.

Stelfonta, a therapy for mast cell cancer based on tigilanol tiglate, was approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2020. (the most common skin tumours in dogs). Since then, the substance has been the subject of human skin, head and neck, and soft tissue cancer clinical trials.

Previous Post

RNA Vaccine UK Innovation Centre At CPI Gets Fresh Funding

Next Post

Pistoia Alliance To Study Clinical Trial Ecology Effect

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Pistoia Alliance To Study Clinical Trial Ecology Effect

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In